High‐Throughput CRISPR/Cas9 Mediated Gene Editing of Primary Human T Cells in a Microfluidic Device for Cellular Therapy Manufacturing (Adv. Mater. Technol. 17/2023)

Cellullar Therapy Manufacturing T cells moving through a microfluidic device are electroporated in continuous-flow for high-throughput cellular therapy manufacturing, as reported by Vishal Tandon and co-workers in article 2300275. The combination of high throughput and high performance enables the scale of processing required for future “off-the-shelf” allogeneic cellular therapies.